Genus plc (LON:GNS - Get Free Report)'s share price hit a new 52-week high during trading on Monday . The company traded as high as GBX 2,160 ($28.70) and last traded at GBX 2,150 ($28.57), with a volume of 25118 shares changing hands. The stock had previously closed at GBX 2,110 ($28.04).
Analysts Set New Price Targets
Separately, Shore Capital restated a "buy" rating on shares of Genus in a research report on Wednesday, April 30th.
Get Our Latest Analysis on Genus
Genus Stock Up 2.1%
The firm's fifty day moving average is GBX 1,818.72 and its 200-day moving average is GBX 1,772.97. The stock has a market capitalization of £1.41 billion, a PE ratio of 178.63, a PEG ratio of 2.87 and a beta of 0.37. The company has a quick ratio of 1.08, a current ratio of 1.80 and a debt-to-equity ratio of 53.12.
Genus (LON:GNS - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.53) earnings per share for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. On average, equities research analysts predict that Genus plc will post 70.9644323 earnings per share for the current year.
Insider Buying and Selling
In other Genus news, insider Jorgen Kokke sold 19,967 shares of the business's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($23.00), for a total value of £345,628.77 ($459,246.31). 0.75% of the stock is owned by insiders.
About Genus
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
